Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.
Recruiting · NCT06626685 · Observational (researchers observe without assigning treatment) · Lead sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed. The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.
Who can take part
Inclusion criteria
- consecutive patients admitted to the Cardiology Unit of the ASST Papa Giovanni XXIII Hospital, Bergamo for acute HF and patients attending the outpatient HF clinic of the same hospital for chronic HF
- age \>18 years
- written informed consent
Exclusion criteria
- chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents
- previous heart transplant
- cardiogenic shock or cardiac arrest
- recent acute coronary syndrome (\<3 months)
- current acute infection requiring specific treatment
- overt MPNs
- primary myelodysplastic syndromes
- malignant cancers
- non-cardiovascular co-morbidity reducing life expectancy to \< 1 year
- any factor precluding 1-year follow-up
Where it is running
2 locations listed.
- ATS BERGAMO Agenzia di Tutela della Salute - Bergamo, Italy
- Asst Papa Giovanni Xxiii - Dip. Di Cardiologia - Bergamo, Italy